vs

Side-by-side financial comparison of CITIZENS, INC. (CIA) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

CITIZENS, INC. is the larger business by last-quarter revenue ($72.1M vs $70.6M, roughly 1.0× Viridian Therapeutics, Inc.\DE). CITIZENS, INC. runs the higher net margin — 10.2% vs -49.0%, a 59.2% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 13.5%). CITIZENS, INC. produced more free cash flow last quarter ($17.5M vs $-84.7M).

Citizen Watch Co., Ltd. , also known as the Citizen Group, is an electronics company primarily known for its watches and is the core company of a Japanese global corporate group based in Nishitokyo, Tokyo, Japan. In addition to Citizen brand watches, it is the parent of American watch company Bulova. Beyond watches, Citizen also manufactures calculators, printers, health care devices, and precision CNC machining equipment.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

CIA vs VRDN — Head-to-Head

Bigger by revenue
CIA
CIA
1.0× larger
CIA
$72.1M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81944.6% gap
VRDN
81958.1%
13.5%
CIA
Higher net margin
CIA
CIA
59.2% more per $
CIA
10.2%
-49.0%
VRDN
More free cash flow
CIA
CIA
$102.3M more FCF
CIA
$17.5M
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CIA
CIA
VRDN
VRDN
Revenue
$72.1M
$70.6M
Net Profit
$7.3M
$-34.6M
Gross Margin
Operating Margin
10.9%
-56.7%
Net Margin
10.2%
-49.0%
Revenue YoY
13.5%
81958.1%
Net Profit YoY
102.7%
54.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIA
CIA
VRDN
VRDN
Q4 25
$72.1M
Q3 25
$62.8M
$70.6M
Q2 25
$65.1M
Q1 25
$55.7M
Q4 24
$63.5M
Q3 24
$61.7M
Q2 24
$62.1M
Q1 24
$57.7M
Net Profit
CIA
CIA
VRDN
VRDN
Q4 25
$7.3M
Q3 25
$2.4M
$-34.6M
Q2 25
$6.5M
Q1 25
$-1.6M
Q4 24
$3.6M
Q3 24
$2.8M
Q2 24
$4.0M
Q1 24
$4.5M
Operating Margin
CIA
CIA
VRDN
VRDN
Q4 25
10.9%
Q3 25
7.1%
-56.7%
Q2 25
10.6%
Q1 25
-3.2%
Q4 24
5.9%
Q3 24
4.9%
Q2 24
5.3%
Q1 24
8.5%
Net Margin
CIA
CIA
VRDN
VRDN
Q4 25
10.2%
Q3 25
3.8%
-49.0%
Q2 25
9.9%
Q1 25
-2.9%
Q4 24
5.7%
Q3 24
4.5%
Q2 24
6.4%
Q1 24
7.9%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIA
CIA
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$23.0M
$490.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$235.0M
$503.0M
Total Assets
$1.8B
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIA
CIA
VRDN
VRDN
Q4 25
$23.0M
Q3 25
$23.1M
$490.9M
Q2 25
$22.7M
Q1 25
$18.4M
Q4 24
$29.3M
Q3 24
$32.4M
Q2 24
$26.3M
Q1 24
$23.2M
Stockholders' Equity
CIA
CIA
VRDN
VRDN
Q4 25
$235.0M
Q3 25
$225.6M
$503.0M
Q2 25
$229.0M
Q1 25
$218.1M
Q4 24
$210.4M
Q3 24
$207.6M
Q2 24
$191.5M
Q1 24
$195.2M
Total Assets
CIA
CIA
VRDN
VRDN
Q4 25
$1.8B
Q3 25
$1.7B
$577.1M
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.7B
Q2 24
$1.7B
Q1 24
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIA
CIA
VRDN
VRDN
Operating Cash FlowLast quarter
$18.0M
$-84.6M
Free Cash FlowOCF − Capex
$17.5M
$-84.7M
FCF MarginFCF / Revenue
24.3%
-120.1%
Capex IntensityCapex / Revenue
0.6%
0.2%
Cash ConversionOCF / Net Profit
2.45×
TTM Free Cash FlowTrailing 4 quarters
$26.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIA
CIA
VRDN
VRDN
Q4 25
$18.0M
Q3 25
$4.7M
$-84.6M
Q2 25
$3.5M
Q1 25
$748.0K
Q4 24
$31.9M
Q3 24
$9.7M
Q2 24
$4.6M
Q1 24
$6.8M
Free Cash Flow
CIA
CIA
VRDN
VRDN
Q4 25
$17.5M
Q3 25
$4.6M
$-84.7M
Q2 25
$3.3M
Q1 25
$641.0K
Q4 24
$31.3M
Q3 24
$9.3M
Q2 24
$4.5M
Q1 24
$6.7M
FCF Margin
CIA
CIA
VRDN
VRDN
Q4 25
24.3%
Q3 25
7.3%
-120.1%
Q2 25
5.1%
Q1 25
1.2%
Q4 24
49.2%
Q3 24
15.1%
Q2 24
7.2%
Q1 24
11.7%
Capex Intensity
CIA
CIA
VRDN
VRDN
Q4 25
0.6%
Q3 25
0.1%
0.2%
Q2 25
0.3%
Q1 25
0.2%
Q4 24
1.0%
Q3 24
0.6%
Q2 24
0.2%
Q1 24
0.1%
Cash Conversion
CIA
CIA
VRDN
VRDN
Q4 25
2.45×
Q3 25
1.93×
Q2 25
0.54×
Q1 25
Q4 24
8.81×
Q3 24
3.48×
Q2 24
1.16×
Q1 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons